Linquette M
Presse Med. 1987 Jun 27;16(25):1234-8.
Known since 1967 and usually familial, the syndrome of tissue resistance to thyroid hormones may take one of two different forms, depending on the receptors involved. When resistance affects both peripheral and pituitary receptors, plasma thyroid hormone levels are high despite the lack of thyrotoxicosis, thyroxine and triiodothyronine are ineffective, even in high dosage, and plasma TSH increases to explode under TRH. When resistance only affects pituitary receptors, there is moderate thyrotoxicosis with paradoxical and inappropriate TSH increase. Contrary to expectations, nuclear receptors to triiodothyronine are perturbed in only a few cases. Reduction of thyrotropic hyperfunction, which is the primary purpose of treatment, can be achieved with D-forms of thyroid hormones or with somatostatin and its derivatives.
自1967年以来为人所知，且通常具有家族性的甲状腺激素组织抵抗综合征可能有两种不同形式之一，这取决于所涉及的受体。当抵抗影响外周和垂体受体时，尽管没有甲状腺毒症，但血浆甲状腺激素水平很高，甲状腺素和三碘甲状腺原氨酸无效，即使大剂量使用也是如此，并且血浆促甲状腺激素（TSH）在促甲状腺激素释放激素（TRH）作用下会激增。当抵抗仅影响垂体受体时，会出现中度甲状腺毒症，伴有矛盾且不适当的TSH升高。与预期相反，仅在少数情况下三碘甲状腺原氨酸的核受体会受到干扰。治疗的主要目的是降低促甲状腺激素功能亢进，这可以通过使用D型甲状腺激素或生长抑素及其衍生物来实现。
